Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Healthcare
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Debt-Free CPH: At 1.5 times its 2020 EBITDA And The Buyback
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(164)
•••
Comment by Northforce13on Feb 24, 2021 8:22pm
122 Views
Post# 32654532

RE:RE:Debt-Free CPH: At 1.5 times its 2020 EBITDA And The Buyback

RE:RE:Debt-Free CPH: At 1.5 times its 2020 EBITDA And The BuybackWhat ur missing is that 10 years ago the share price was the same as it is today.  So if you bought regular stocks 10 years ago ur up 150%.  If you bought this, ur up 0%. 

Cuz they sometimes make really dumb acquisitions then have to write them off, wiping out all their profits.

U shud maybe research these things before you buy, instead of buying then asking others what ur missing.

Like another poster pointed out, the latest write off is 5 mil, wiping out the entire year's profits thus far.  Maybe you missed that post.  Or maybe you missed the press release from the company.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities